A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.

[1]  W. Wahli,et al.  Peroxisome Proliferator Activated Receptors , 2005 .

[2]  H. Aburatani,et al.  Peroxisome Proliferator-Activated Receptor Gamma Agonist Ligands Stimulate a Th2 Cytokine Response and Prevent Acute Colitis , 2002, Inflammatory bowel diseases.

[3]  J. Miyazaki,et al.  IL-15-Dependent Activation-Induced Cell Death-Resistant Th1 Type CD8αβ+NK1.1+ T Cells for the Development of Small Intestinal Inflammation1 , 2002, The Journal of Immunology.

[4]  J. Stephens,et al.  Interferon-γ-mediated Activation and Ubiquitin-Proteasome-dependent Degradation of PPARγ in Adipocytes* , 2002, The Journal of Biological Chemistry.

[5]  A. Nakajima,et al.  PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease , 2001 .

[6]  M. Kay,et al.  A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob , 2001, Gene Therapy.

[7]  J. Auwerx,et al.  Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer , 2001, The Journal of experimental medicine.

[8]  T. Mayumi,et al.  Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. , 2001, Biochemical and biophysical research communications.

[9]  Judy H. Cho,et al.  Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. , 2001, The Journal of clinical investigation.

[10]  R. Blumberg,et al.  Prospects for research in inflammatory bowel disease. , 2001, JAMA.

[11]  Y. Terauchi,et al.  Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury , 2001 .

[12]  F. Shanahan,et al.  Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. , 2001, Gastroenterology.

[13]  R. Evans,et al.  PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.

[14]  S. Snapper,et al.  Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. , 2000, Gastroenterology.

[15]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[16]  C. Glass,et al.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. , 1999, Current opinion in biotechnology.

[18]  M. Akens,et al.  Quantitative Real-Time PCR for Equine Cytokine mRNA in Nondecalcified Bone Tissue Embedded in Methyl Methacrylate , 1999, Calcified Tissue International.

[19]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[20]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[21]  M. Kay,et al.  A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. , 1999, Human gene therapy.

[22]  J. Vamecq,et al.  Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.

[23]  S. Mordon,et al.  Endoscopic fluorescence imaging for the study of anastomotic recurrences in Crohn's disease (CD) correlation with histological findings , 1999 .

[24]  M. Kay,et al.  Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. , 1998, Human gene therapy.

[25]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[26]  I. Singer,et al.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. , 1998, Gastroenterology.

[27]  W. Wahli,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Differential Expression of Peroxisome Proliferator- Activated Receptor-�,-�, and- � during Rat , 2022 .

[28]  O. Nielsen,et al.  Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. , 1997, The American journal of gastroenterology.

[29]  K. Stecker,et al.  An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[30]  B. Spiegelman,et al.  Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.

[31]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[32]  F. Graham,et al.  The use of adenoviral vectors for gene therapy and gene transfer in vivo. , 1995, Current opinion in biotechnology.

[33]  A. Laupacis,et al.  Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. , 1994, The New England journal of medicine.

[34]  Y. Kanegae,et al.  A simple and efficient method for purification of infectious recombinant adenovirus. , 1994, Japanese journal of medical science & biology.